Fluorescence immunoassay is a sensitive technique that is used in the measurement of many compounds, including drugs, hormones, and proteins; in the identification of antibodies; and in the quantification of antigens such as viral particles and, potentially, bacteria. The fluorescence detection system includes higher sensitivity detection of the analyte, simplified reagents, and simpler assay designs. A modern fluorescent-based immunoassay uses as the detection reagent a fluorescent compound that absorbs light or energy (excitation energy) at a specific wavelength and then emits light or energy at a different wavelength.
Hoffman-La Roche Ltd. And Thermo Fisher Scientific, Inc. – Notable Participants in Fluorescent Immunoassay Market
A few of the most notable companies occupying a considerable share of the market are Abbott, BD, bioMerieux SA, F. Hoffman-La Roche Ltd., Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Quidel Corp., Ortho Clinical Diagnostics Holdings plc, and Danaher.
Market leaders are involved in partnerships, product launches, acquisitions, and other strategies to improve their performance and consolidate the market position. The companies are focusing on organic strategies such as product launches, and product approvals. Inorganic growth strategies witnessed in the market were acquisitions, collaboration, and partnerships. These growth strategies have aided the market players in the expansion of their business and enhanced their geographic presence. Additionally, growth strategies such as acquisitions and partnerships helped in strengthening their customer base and increase the product portfolio.
A few of the vital developments in the fluorescent immunoassay market are mentioned below:
| Year | News |
| Mar-2022 | Quidel Corporation acquired Ortho Clinical Diagnostics with the transaction expected to close during the first half of the fiscal year 2022. The combined organization will unite the companies’ technologies and platforms to benefit customers with expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings. |
| Jun-2021 | Danaher (Beckman Coulter) took over the distribution to customers of a B-type Natriuretic Peptide (BNP) assay, a marker of congestive heart failure on the company’s immunoassay platforms. The BNP assay for Beckman Coulter immunoassay analyzers, currently sold as TRIAGE BNP by Quidel would now be sold by Beckman Coulter under the brand name Access BNP. Laboratories will have continued supply of the high-quality BNP assay that exclusively runs on Beckman Coulter immunoassay platforms. |
| Jun-2021 | Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of SARS-CoV-2 infections. The laboratory-based Elecsys SARS-CoV-2 Antigen test had earlier received CE mark and has recently obtained the import license from CDSCO |
| May-2021 | In conjunction with clinical findings and the results of other laboratory testing, BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes were launched to help clinicians determine the risks of Intubation with Mechanical Ventilation and also of mortality in COVID-19 patients, aiding in-patient management decisions. The BD Multitest 6-Color TBNK Reagent with optional BD Trucount Tubes was licensed by Health Canada as a 6-color direct immunofluorescence reagent for use with a suitably equipped BD flow cytometer to identify and determine the percentages and absolute counts of T, B and natural killer (NK) cells, as well as the CD4 and CD8 subpopulations of T cells in peripheral blood. The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes can be used with the BD FACS Loader and the BD FACS Universal Loader. |
